The Food and Drug Administration has approved Ozempic ® (semaglutide) to reduce the risk of sustained estimated glomerular ...

The Food and Drug Administration (FDA) has approved Symbravo ® (meloxicam/rizatriptan) for the acute treatment of migraine with or without aura in adults.

“Beneficial pediatric obesity treatment response yielded enduring health benefits, markedly lowering future morbidity and mortality risks in young adulthood,” the authors write. Several authors ...

The Food and Drug Administration (FDA) has approved Journavx™ (suzetrigine) for the treatment of moderate to severe acute pain in adults.

The approval of Spravato for the monotherapy indication in TRD was supported by data from the randomized, double-blind, ...

The Food and Drug Administration (FDA) has approved Avtozma ® (tocilizumab-anoh), a biosimilar to Actemra ® (tocilizumab), in both intravenous (IV) and subcutaneous (SC) formulations.

For patients with heart failure (HF), a greater focus on medication management may be needed in order to mitigate HF exacerbations caused by certain ...

HealthDay News — Heart disease continues to be a leading cause of death, according to a report from the American Heart Association published online January 27 in Circulation.

HealthDay News — Fasting plasma glucose (FPG), age, body mass index (BMI), and male sex are all associated with development of diabetes, according to a study published online January 23 in JAMA ...

The Food and Drug Administration (FDA) has accepted for Priority Review the New Drug Application for SL1009 (sodium dichloroacetate oral solution) for the treatment of pyruvate dehydrogenase complex ...

Dapagliflozin plus calorie restriction beneficial for patients with overweight or obesity and type 2 diabetes.

HealthDay News — Kansas health officials are tackling the largest tuberculosis (TB) outbreak in US history, with 67 confirmed cases since the start of 2025.